SCHEMBL14916013

SCHEMBL14916013

O=Cc1ccc(O)c2c1OCOO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 2/20 0.38
TRIM33 Q9UPN9 2/20 0.38
ERN1 O75460 9/20 0.36
AOC3 Q16853 1/20 0.34
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
PRKDC P78527 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
HSP90AA1 P07900 1/20 0.33
IDO1 P14902 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TYR P14679 2/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30705318 0.85 TRIM24 (0.43) TRIM24TRIM33ERN1AOC3PIK3CD
SCHEMBL22853919 0.85 TRIM24 (0.43) TRIM24TRIM33ERN1AOC3PIK3CD
SCHEMBL30705299 0.78 TRIM24 (0.43) TRIM24TRIM33ERN1PIK3CDPIK3CA
SCHEMBL28501401 0.78 TRIM24 (0.43) TRIM24TRIM33ERN1PIK3CDPIK3CA
SCHEMBL6852501 0.77 TDP1 (0.46) TRIM24TRIM33ERN1AOC3MEN1
SCHEMBL6851157 0.68 TDP1 (0.46) TRIM24TRIM33ERN1PIK3CDPIK3CA
SCHEMBL28784850 0.67 AOC3 (0.41) TRIM24TRIM33ERN1AOC3PRKDC
SCHEMBL10430741 0.66 ERN1 (0.44) TRIM24TRIM33ERN1AOC3KMT2A
SCHEMBL21017668 0.66 ALDH1A1 (0.45) ERN1AOC3KDM4ENPSR1LMNA
SCHEMBL2265157 0.65 AOC3 (0.44) AOC3PIK3CAKDM4ENPC1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9884041-B2 Composition for the prevention or treatment of obesity, dyslipidaemia, fatty liver or insulin resistance syndrome, comprising piperonal as an active ingredient YONSEI UNIVERSITY TECHNOLOGY HOLDINGS, INC. (KR) 2018-02-06 US disclosed
US-20130116315-A1 COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY, DYSLIPIDAEMIA, FATTY LIVER OR INSULIN RESISTANCE SYNDROME, COMPRISING PIPERONAL AS AN ACTIVE INGREDIENT NOVA K HEALTH CO., LTD (KR) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116315-A1 COMPOSITION FOR THE PREVENTION OR TREATMENT OF OBESITY, DYSLIPIDAEMIA, FATTY LIVER OR INSULIN RESISTANCE SYNDROME, COMPRISING PIPERONAL AS AN ACTIVE INGREDIENT LIPC, PNLIP, CPT1A TRIM24 2734/4885TRIM33 2049/4885ERN1 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.